Daniel W. Muehl, See Remarks at Clovis Oncology, Inc. (CLVS), sold 248 shares at $3.00 ($744) on 2021-12-02, disclosed to the SEC on 2021-12-03.
Seasonal sale ($744) by See Remarks — this insider has traded CLVS in December in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| CLVS | SELL | 2022-08-03 | $7K | — | Filing → |
| CLVS | SELL | 2022-06-03 | $1K | — | Filing → |
| CLVS | SELL | 2022-05-03 | $9K | — | Filing → |